<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00995839</url>
  </required_header>
  <id_info>
    <org_study_id>1065</org_study_id>
    <nct_id>NCT00995839</nct_id>
  </id_info>
  <brief_title>Terlipressin in Septic Shock: Effects on Microcirculation</brief_title>
  <official_title>Vasopressin Receptor Agonists in Septic Shock: Effects on Microcirculation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Roma La Sapienza</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Roma La Sapienza</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study was conducted as a prospective, randomized study to investigate the effects
      of vasopressin receptor agonists terlipressin and vasopressin on systemic hemodynamics and
      microcirculation in patients with catecholamine-dependent septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      60 septic shock patients requiring norepinephrine to maintain mean arterial pressure between
      65 and 75 mmHg despite adequate volume resuscitation will be enrolled in the study. After an
      initial hemodynamic resuscitation aimed at achieve a mean arterial pressure between 65 and 75
      mmHg and normovolemia, patients will be randomly allocated to be treated with either a)
      intravenous administration of terlipressin 1 µg∙kg-1∙h-1 for 6 hrs, b) intravenous
      administration of arginine vasopressin 0.04 UI∙min-1 for 6 hrs, c) intravenous administration
      of terlipressin bolus dose of 0.5 mg (each n = 20). In all groups open label norepinephrine
      will be additionally administered to maintain a mean arterial pressure (MAP) between 65 and
      75 mmHg, if necessary. Data from right heart catheterization and sublingual microvascular
      network will be obtained just before randomization (baseline) and then after 6 hours in the
      vasopressin, terlipressin infusion and terlipressin bolus groups.

      The sublingual microvascular network will be studied using the sidestream dark field
      (SDF)imaging. The device will be applied on the lateral side of the tongue, in an area
      approximately 2-4 cm from the tip of the tongue. Sequences of 10 secs from eight adjacent
      areas will be recorded on disk using a personal computer. These sequences will be later
      analyzed by an investigator blinded to the patient's diagnosis and therapy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systemic hemodynamic and Microcirculatory flow index of small and medium vessels (MFI)</measure>
    <time_frame>over a period of 6 hrs from the time of randomization</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oxygen transport variables</measure>
    <time_frame>over a period of 6 from the time of randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acid-base homeostasis</measure>
    <time_frame>over a period of 6 hrs from the time of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional capillary density (mm/mm2) (FCD)</measure>
    <time_frame>over a period of 6 hrs from the time of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>De Backer score</measure>
    <time_frame>over a period of 6 hrs from the time of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perfused Vessel Density (PVD) (mm/mm2)</measure>
    <time_frame>over a period of 6 hrs from the time of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Perfused vessels (%) (PPV)</measure>
    <time_frame>over a period of 6 hrs from the time of randomization</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Septic Shock</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>continuous terlipressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>vasopressin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>terlipressin bolus dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>continuous infusion of terlipressin</intervention_name>
    <description>Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs</description>
    <arm_group_label>continuous terlipressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arginine vasopressin</intervention_name>
    <description>Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs</description>
    <arm_group_label>vasopressin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>terlipressin bolus administration</intervention_name>
    <description>intravenous terlipressin bolus administration at the dose of 0.5 mg</description>
    <arm_group_label>terlipressin bolus dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of septic shock

          -  Vasopressor support to maintain mean arterial pressure (MAP) between 65 and 75 mmHg
             despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18
             mmHg and central venous pressure = 8-12 mmHg)

        Exclusion Criteria:

          -  Pregnancy

          -  Age &lt; 18 years

          -  Present or suspected acute mesenteric ischemia

          -  Vasospastic diathesis (e.g. Raynaud's syndrome or related diseases)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Morelli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rome &quot;La Sapienza&quot;, Department of Anesthesiology and Intensive Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departement of Anesthesiology and Intensive Care</name>
      <address>
        <city>Rome</city>
        <state>I</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2009</study_first_submitted>
  <study_first_submitted_qc>October 14, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2009</study_first_posted>
  <last_update_submitted>February 3, 2010</last_update_submitted>
  <last_update_submitted_qc>February 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Andrea Morelli</name_title>
    <organization>University of Rome &quot;La Sapienza&quot;</organization>
  </responsible_party>
  <keyword>terlipressin</keyword>
  <keyword>vasopressin</keyword>
  <keyword>sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>norepinephrine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vasopressins</mesh_term>
    <mesh_term>Arginine Vasopressin</mesh_term>
    <mesh_term>Lypressin</mesh_term>
    <mesh_term>Terlipressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

